Evidence map›Paper›PMID 29997961›Full record

ArticleJournal of thoracic disease2018

The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer.

Tangfeng Lv, Qian Zou, Zhengbo Song, Hongbing Liu, Qiming Wang, Yong Song

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Tangfeng LvDepartment of Respiratory Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Qian ZouDepartment of Respiratory Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Zhengbo SongDepartment of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Hongbing LiuDepartment of Respiratory Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Qiming WangDepartment of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.
Yong SongDepartment of Respiratory Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Nanjing General Hospital of Nanjing Military Command · CNNanjing University · CNZhejiang Cancer Hospital · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) patients with

methodsA total of 52 ALK-positive advanced NSCLC patients were enrolled. The genetic variation was revealed by NGS. We identified different

resultsAmong the group that was detected with ALK+ fusion by immunohistochemistry (IHC), patients detected as ALK- fusion by the NGS method were associated with a shorter progression-free survival (PFS) compared with ALK+ patients by NGS. Moreover, for different

conclusionsIt is necessary to use multiple methods together to detect

Indexed as

additional coexisting mutations (ACMs)ALK fusion typesALK-positive non-small cell lung cancer (ALK-positive NSCLC)molecular heterogeneityNext-generation sequencing (NGS)

Identifiers

PMID29997961
PMCPMC6006122
OpenAlexW2803978573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.